Viropro Net Income
In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Viropro, as well as the relationship between them.
Viropro Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Loss | -1.2 M | -1.2 M | |
| Net Loss | -1.2 M | -1.2 M | |
| Net Loss | -1.2 M | -1.2 M |
Viropro | Net Income | Build AI portfolio with Viropro Stock |
Evaluating Viropro's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Viropro's fundamental strength.
Latest Viropro's Net Income Growth Pattern
Below is the plot of the Net Income of Viropro over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Viropro financial statement analysis. It represents the amount of money remaining after all of Viropro operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Viropro's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Viropro's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (1.01 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Viropro Net Income Regression Statistics
| Arithmetic Mean | (1,058,143) | |
| Coefficient Of Variation | (11.44) | |
| Mean Deviation | 79,050 | |
| Median | (1,010,149) | |
| Standard Deviation | 121,078 | |
| Sample Variance | 14.7B | |
| Range | 454.8K | |
| R-Value | 0.09 | |
| Mean Square Error | 15.5B | |
| R-Squared | 0.01 | |
| Significance | 0.73 | |
| Slope | 2,208 | |
| Total Sum of Squares | 234.6B |
Viropro Net Income History
Other Fundumenentals of Viropro
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Viropro Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Viropro is extremely important. It helps to project a fair market value of Viropro Stock properly, considering its historical fundamentals such as Net Income. Since Viropro's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Viropro's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Viropro's interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Viropro diversify its offerings? Factors like these will boost the valuation of Viropro. If investors know Viropro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Viropro data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Revenue Growth 1.19 |
Understanding Viropro requires distinguishing between market price and book value, where the latter reflects Viropro's accounting equity. The concept of intrinsic value - what Viropro's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viropro's price substantially above or below its fundamental value.
Please note, there is a significant difference between Viropro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Viropro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viropro's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Viropro 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Viropro's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Viropro.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Viropro on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Viropro or generate 0.0% return on investment in Viropro over 90 days. Viropro Inc., through its subsidiaries, engages in the contract research, development, and manufacture of biotherapeutic... More
Viropro Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Viropro's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Viropro upside and downside potential and time the market with a certain degree of confidence.
Viropro Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Viropro's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Viropro's standard deviation. In reality, there are many statistical measures that can use Viropro historical prices to predict the future Viropro's volatility.Viropro Backtested Returns
We have found zero technical indicators for Viropro, which you can use to evaluate the volatility of the company. The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Viropro are completely uncorrelated.
Auto-correlation | 0.00 |
No correlation between past and present
Viropro has no correlation between past and present. Overlapping area represents the amount of predictability between Viropro time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Viropro price movement. The serial correlation of 0.0 indicates that just 0.0% of current Viropro price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.0 | |
| Spearman Rank Test | 1.0 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Viropro Operating Income
Based on the recorded statements, Viropro reported net income of (1.01 Million). This is 100.3% lower than that of the Biotechnology sector and 101.44% lower than that of the Health Care industry. The net income for all United States stocks is 100.18% higher than that of the company.
Viropro Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Viropro's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Viropro could also be used in its relative valuation, which is a method of valuing Viropro by comparing valuation metrics of similar companies.Viropro is currently under evaluation in net income category among its peers.
Viropro Fundamentals
| Operating Margin | (2.09) % | ||||
| Current Valuation | 11.91 M | ||||
| Shares Outstanding | 916.09 M | ||||
| Price To Earning | 0.10 X | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 18.15 X | ||||
| Revenue | 571.1 K | ||||
| Net Income | (1.01 M) | ||||
| Cash And Equivalents | 119.25 K | ||||
| Total Debt | 175.56 K | ||||
| Debt To Equity | 0.57 % | ||||
| Book Value Per Share | 0.02 X | ||||
| Cash Flow From Operations | (675.62 K) | ||||
| Beta | -0.99 | ||||
| Market Capitalization | 18.32 K | ||||
| Total Asset | 2.11 M | ||||
| Retained Earnings | (17 M) | ||||
| Working Capital | (2.87 M) | ||||
| Current Asset | 291 K | ||||
| Current Liabilities | 3.16 M | ||||
| Net Asset | 2.11 M |
About Viropro Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Viropro's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Viropro using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Viropro based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Viropro
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Viropro position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viropro will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Viropro could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Viropro when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Viropro - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Viropro to buy it.
The correlation of Viropro is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Viropro moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Viropro moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Viropro can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out To learn how to invest in Viropro Stock, please use our How to Invest in Viropro guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Will Biotechnology sector continue expanding? Could Viropro diversify its offerings? Factors like these will boost the valuation of Viropro. If investors know Viropro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Viropro data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Revenue Growth 1.19 |
Understanding Viropro requires distinguishing between market price and book value, where the latter reflects Viropro's accounting equity. The concept of intrinsic value - what Viropro's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Viropro's price substantially above or below its fundamental value.
Please note, there is a significant difference between Viropro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Viropro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Viropro's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.